ROTHBLATT MARTINE A sold $5.2M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $549.32 ($544.69–$552.89, $5.22M total) across 9 trades on 2026-06-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the CEO/Chair’s $5.22M open-market sale executed June 9, with the trades covered by a pre-arranged 10b5-1 plan.
Market read
This provides a fresh, primary-source datapoint on insider activity, but it does not introduce new operational or financial information.
What to watch
Traders may over-weight insider sales; without accompanying fundamentals (earnings, trial, guidance, regulatory action), the signal is usually weak.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
SEC Form 4 shows UTHR CEO/Chair Martine Rothblatt sold $5.22M of United Therapeutics shares via an open-market transaction under a 10b5-1 plan.
Likely limited/short-lived impact; any reaction would be more sentiment-driven than fundamental.
The filing is a primary-source insider transaction with defined parameters (10b5-1, weighted-average price, post-sale holdings), but it does not disclose new company fundamentals or guidance.
Market effects
Minimal; this is company-specific insider activity with no sector-wide catalyst described.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider transaction disclosure.
- insiderMartine A. Rothblatt
Chairperson & CEO who sold shares under a 10b5-1 plan.
